



US007731975B2

(12) **United States Patent**
Grogan et al.

(10) **Patent No.:** **US 7,731,975 B2**
(45) **Date of Patent:** **Jun. 8, 2010**

(54) **CHIMERIC FILOVIRUS GLYCOPROTEIN**

(75) Inventors: **Case C. Grogan**, Gaithersburg, MD (US); **Michael C. Hevey**, Frederick, MD (US); **Alan L. Schmaljohn**, Frederick, MD (US)

(73) Assignee: **The United States of America as Represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1892 days.

(21) Appl. No.: **10/066,506**

(22) Filed: **Jan. 31, 2002**

(65) **Prior Publication Data**

US 2003/0108560 A1 Jun. 12, 2003

Related U.S. Application Data

(60) Provisional application No. 60/267,522, filed on Jan. 31, 2001.

(51) **Int. Cl.**

A61K 39/295 (2006.01)
A61K 39/12 (2006.01)
C12N 15/00 (2006.01)

(52) **U.S. Cl.** **424/202.1**; 424/204.1; 435/320.1

(58) **Field of Classification Search** 435/5, 435/6, 69.7, 339; 330/387.3; 424/192.1, 424/186.1, 202.1, 204.1; 536/23.72

See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO0000616 1/2000
WO WO0000617 1/2000

OTHER PUBLICATIONS

Partidos, C., et al., 1992(a), "The effect of orientation of epitopes on the immunogenicity of chimeric synthetic peptides representing

measles virus protein sequences", *Mol. Immunol.* 29(5):651-8 (abstract provided).*

Partidos, C., et al., 1992(b), "The effects of a flanking sequence on the immune response to a B and a T cell epitope from the fusion protein of measles virus.", *J. Gen. Virol.* 73(8):1987-94 (abstract provided).*

Janssen, R., et al., 1994, "Influence of amino acids of a carrier protein flanking an inserted T cell determinant on T cell stimulation.", *Internat. Immunol.* 6(8):1187-1193 (abstract provided).*

Eisenlohr, L. C., et al., 1992, "Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes.", *J. Exp. Med.* 175(2):481-7 (abstract provided).*

Ayato, T., et al., 2003, "Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses.", *J. Virol.* 77(2):1069-74 (abstract provided).*

London, S. D. et al., 1992. Infectious enveloped RNA virus antigenic chimeras. *PNAS*, 89, 207-211.

Klenk Hans Dieter et al., 2001. Symposium on Marburg and Ebola viruses. *Virus Research* 80, 117-123.

* cited by examiner

Primary Examiner—J. S. Parkin

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57) **ABSTRACT**

Chimeric GP molecules were constructed which contain portions of both the EBOV and MBGV GP proteins by swapping the subunits between EBOV and MBGV. The chimeric molecules were cloned into an alphavirus replicon which offers the advantage of high protein expression levels in mammalian cells and is a proven vaccine vector. These chimeric molecules fully protected guinea pigs from MBGV challenge, and conversely protected the animals from EBOV challenge. These results indicate that a protective epitope resides within the GP2 subunit of the MBGV GP protein and at least partially within the GP2 subunit of the EBOV GP protein. Additionally these results show that a construction of a single-component bivalent vaccine protective in guinea pigs is achievable.

37 Claims, 13 Drawing Sheets